Home
CERT
CERT News

Latest Certara Inc. (CERT) News on October 24, 2025

Argus Research

4 months ago

CERT: Raising target price to $9.00

Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return

Simply Wall St.

4 months ago

Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return

Argus Research

4 months ago

CERT: Raising target price to $10.00

Argus Research

5 months ago

CERT: Lowering target price to $9.00

Argus Research

5 months ago

CERT: Raising target price to $10.00

Certara, Inc. (NASDAQ:CERT) Shares Could Be 27% Above Their Intrinsic Value Estimate

Simply Wall St.

6 months ago

Certara, Inc. (NASDAQ:CERT) Shares Could Be 27% Above Their Intrinsic Value Estimate

Certara First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

6 months ago

Certara First Quarter 2025 Earnings: Beats Expectations

Argus Research

6 months ago

CERT: Lowering target price to $9.00

Thomson Reuters StreetEvents

6 months ago

Q1 2025 Certara Inc Earnings Call

MT Newswires

6 months ago

Certara Q1 Adjusted Earnings, Revenue Increase; 2025 Outlook Reaffirmed

Certara Inc (CERT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

6 months ago

Certara Inc (CERT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates

Zacks

6 months ago

Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates

Certara Reports First Quarter 2025 Financial Results

GlobeNewswire

6 months ago

Certara Reports First Quarter 2025 Financial Results

Certara to Participate in Upcoming Investor Conferences

GlobeNewswire

6 months ago

Certara to Participate in Upcoming Investor Conferences

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

6 months ago

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?

Zacks

6 months ago

Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?

Argus Research

6 months ago

CERT: Raising target price to $12.00

Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?

Zacks

6 months ago

Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?

Argus Research

6 months ago

CERT: Raising target price to $11.00

Why Certara Inc. (CERT) Skyrocketed On Monday?

Insider Monkey

6 months ago

Why Certara Inc. (CERT) Skyrocketed On Monday?

MT Newswires

6 months ago

Certara Launches Product for Biopharmaceutical Firms to Reduce Reliance on Animal Testing

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Monday

MT Newswires

6 months ago

Sector Update: Health Care

MT Newswires

6 months ago

Certara's Preliminary Q1 Revenue Increases; Reiterates 2025 Outlook; Authorizes $100 Million Share Buyback Plan

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

GlobeNewswire

6 months ago

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization

GlobeNewswire

6 months ago

Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization

Why Certara Inc. (CERT) Soared Last Week?

Insider Monkey

6 months ago

Why Certara Inc. (CERT) Soared Last Week?

Why Certara Inc. (CERT) Surged On Friday?

Insider Monkey

6 months ago

Why Certara Inc. (CERT) Surged On Friday?

Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?

Zacks

6 months ago

Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?

Argus Research

7 months ago

CERT: What does Argus have to say about CERT?

Argus Research

7 months ago

CERT: Lowering target price to $8.00

GlobeNewswire

7 months ago

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

At US$9.91, Is Certara, Inc. (NASDAQ:CERT) Worth Looking At Closely?

Simply Wall St.

7 months ago

At US$9.91, Is Certara, Inc. (NASDAQ:CERT) Worth Looking At Closely?

Argus Research

7 months ago

CERT: What does Argus have to say about CERT?

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

Zacks

7 months ago

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

Certara, Inc. (CERT): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts

Insider Monkey

8 months ago

Certara, Inc. (CERT): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts

Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

GlobeNewswire

8 months ago

Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

Argus Research

8 months ago

CERT: Lowering target price to $9.00

MT Newswires

8 months ago

TD Cowen Initiates Coverage on Certara With Buy Rating, $16 Price Target

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Certara Inc Earnings Call

Certara Inc (CERT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions

GuruFocus.com

8 months ago

Certara Inc (CERT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions

Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates

Zacks

8 months ago

Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates

Certara Reports Fourth Quarter 2024 Financial Results

GlobeNewswire

8 months ago

Certara Reports Fourth Quarter 2024 Financial Results

Argus Research

8 months ago

CERT: Lowering target price to $10.00

HPQ Set to Report Q1 Earnings: What's in the Cards for the Stock?

Zacks

8 months ago

HPQ Set to Report Q1 Earnings: What's in the Cards for the Stock?

Argus Research

8 months ago

CERT: What does Argus have to say about CERT?

Certara, Inc. (CERT): Among the Health Information Services Stocks Outpacing the Market in 2025

Insider Monkey

8 months ago

Certara, Inc. (CERT): Among the Health Information Services Stocks Outpacing the Market in 2025

Argus Research

9 months ago

CERT: What does Argus have to say about CERT?

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Zacks

9 months ago

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

GlobeNewswire

9 months ago

Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

Argus Research

9 months ago

CERT: Raising target price to $11.00

Certara Inc. (CERT): Accelerating Drug Development with AI Amid Leerink’s Target Price Boost to $13

Insider Monkey

9 months ago

Certara Inc. (CERT): Accelerating Drug Development with AI Amid Leerink’s Target Price Boost to $13

Exploring High Growth Tech Stocks in January 2025

Simply Wall St.

9 months ago

Exploring High Growth Tech Stocks in January 2025

Argus Research

9 months ago

CERT: Raising target price to $10.00

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

9 months ago

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

Argus Research

9 months ago

CERT: What does Argus have to say about CERT?

Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around

Simply Wall St.

10 months ago

Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around

Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Argus Research

10 months ago

CERT: What does Argus have to say about CERT?

Argus Research

10 months ago

CERT: Lowering target price to $9.00

Argus Research

10 months ago

CERT: Raising target price to $10.00

Cautious Spending By Large Biopharma Client Dragged Certara (CERT) in Q3

Insider Monkey

a year ago

Cautious Spending By Large Biopharma Client Dragged Certara (CERT) in Q3

Argus Research

a year ago

CERT: What does Argus have to say about CERT?

Certara Showcases 2024 Research Wins With Over 100 Papers Published

GlobeNewswire

a year ago

Certara Showcases 2024 Research Wins With Over 100 Papers Published

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

a year ago

Exploring Three High Growth Tech Stocks In The United States

Argus Research

a year ago

CERT: What does Argus have to say about CERT?

Soft Biotech Funding and Cost-Cutting Dragged Certara (CERT) in Q3

Insider Monkey

a year ago

Soft Biotech Funding and Cost-Cutting Dragged Certara (CERT) in Q3

Argus Research

a year ago

CERT: Raising target price to $10.00

Thomson Reuters StreetEvents

a year ago

Q3 2024 Certara Inc Earnings Call

Certara Inc (CERT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

a year ago

Certara Inc (CERT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Certara, Inc. (CERT) Q3 Earnings Surpass Estimates

Zacks

a year ago

Certara, Inc. (CERT) Q3 Earnings Surpass Estimates

Certara Reports Third Quarter 2024 Financial Results

GlobeNewswire

a year ago

Certara Reports Third Quarter 2024 Financial Results

Argus Research

a year ago

CERT: What does Argus have to say about CERT?

Certara to Participate in the Stephens Annual Investment Conference

GlobeNewswire

a year ago

Certara to Participate in the Stephens Annual Investment Conference

Certara, Inc. (NASDAQ:CERT) Shares Could Be 23% Above Their Intrinsic Value Estimate

Simply Wall St.

a year ago

Certara, Inc. (NASDAQ:CERT) Shares Could Be 23% Above Their Intrinsic Value Estimate

Certara Appoints John Reynders as New Independent Board Member

GlobeNewswire

a year ago

Certara Appoints John Reynders as New Independent Board Member

MaxCyte Appoints Cynthia Collins to its Board of Directors

GlobeNewswire

a year ago

MaxCyte Appoints Cynthia Collins to its Board of Directors

Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024

GlobeNewswire

a year ago

Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024

Argus Research

a year ago

CERT: What does Argus have to say about CERT?

MT Newswires

a year ago

Certara Completes Chemaxon Acquisition

Certara Completes Acquisition of Chemaxon

GlobeNewswire

a year ago

Certara Completes Acquisition of Chemaxon

High Growth Tech Stocks To Watch In September 2024

Simply Wall St.

a year ago

High Growth Tech Stocks To Watch In September 2024

MT Newswires

a year ago

Certara is Well-Positioned for Double-Digit Growth in Biosimulation Software Sales, UBS Says

MT Newswires

a year ago

UBS Upgrades Certara to Buy From Neutral, Price Target Remains $16

Certara’s Simcyp Consortium Celebrates 25th Anniversary

GlobeNewswire

a year ago

Certara’s Simcyp Consortium Celebrates 25th Anniversary

Following a 22% decline over last year, recent gains may please Certara, Inc. (NASDAQ:CERT) institutional owners

Simply Wall St.

a year ago

Following a 22% decline over last year, recent gains may please Certara, Inc. (NASDAQ:CERT) institutional owners

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug

GlobeNewswire

a year ago

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug

Should You Increase Your Holdings in Certara (CERT)?

Insider Monkey

a year ago

Should You Increase Your Holdings in Certara (CERT)?

Should You Think About Buying Certara, Inc. (NASDAQ:CERT) Now?

Simply Wall St.

a year ago

Should You Think About Buying Certara, Inc. (NASDAQ:CERT) Now?

Certara, Inc. (CERT): Among The Best Medical AI Companies

Insider Monkey

a year ago

Certara, Inc. (CERT): Among The Best Medical AI Companies

Argus Research

a year ago

CERT: Raising target price to $11.00

Certara to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Certara to Participate in Upcoming Investor Conferences

Argus Research

a year ago

CERT: What does Argus have to say about CERT?

Certara Launches Phoenix™ Version 8.5 Drug Development Software

GlobeNewswire

a year ago

Certara Launches Phoenix™ Version 8.5 Drug Development Software

Here’s Why Certara (CERT) Stock Underperformed in Q2

Insider Monkey

a year ago

Here’s Why Certara (CERT) Stock Underperformed in Q2

MT Newswires

a year ago

Morgan Stanley Lowers Price Target on Certara to $16 From $21, Keeps Equalweight Rating

Thomson Reuters StreetEvents

a year ago

Q2 2024 Certara Inc Earnings Call

MT Newswires

a year ago

UBS Adjusts Certara Price Target to $16 From $20, Maintains Neutral Rating

MT Newswires

a year ago

Certara's Q2 Adjusted Earnings Fall, Revenue Increases; Reaffirms 2024 Guidance

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Zacks

a year ago

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Share on Social Networks: